Abstract Library

#1316 Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort.

Introduction: LOXL2 is a key protein to epithelial to mesenchymal transition. We showed LOXL2 has a role as a prognostic marker in 115 GEP-NET cases (training cohort (TC)).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Barriuso J, Benavent M, Lamarca A, Bernal E, Guerra-Pastrian L,

Keywords: LOXL2,

#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ambrosio M, Guerra A, Lupo S, Bondanelli M, Sartori S,

Keywords: Everolimus, GEP-NET, efficacy, side effects,